Abstract
Here, we describe a procedure and first-in-man clinical effects of adoptive transfer of ex vivo expanded CD4+CD25+CD127- T regulatory cells (Tregs) in the treatment of graft versus host disease (GvHD). The cells were sorted from buffy coats taken from two family donors, expanded ex vivo and transferred to respective recipients who suffered from either acute or chronic GvHD. The therapy allowed for significant alleviation of the symptoms and reduction of pharmacologic immunosuppression in the case of chronic GvHD, while in the case of grade IV acute GvHD it only transiently improved the condition, for the longest time within all immunosuppressants used nonetheless.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Adoptive Transfer*
-
Adult
-
Bone Marrow Transplantation / adverse effects
-
Bone Marrow Transplantation / immunology
-
CD4 Antigens / immunology
-
Chronic Disease
-
Female
-
Graft vs Host Disease / immunology
-
Graft vs Host Disease / therapy*
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Interleukin-2 Receptor alpha Subunit / immunology
-
Interleukin-7 Receptor alpha Subunit / immunology
-
Leukemia, Myeloid / drug therapy
-
Leukemia, Myeloid / immunology
-
Male
-
Myelodysplastic Syndromes / drug therapy
-
Myelodysplastic Syndromes / immunology
-
Stem Cell Transplantation / adverse effects
-
T-Lymphocytes, Regulatory / immunology
-
T-Lymphocytes, Regulatory / transplantation*
Substances
-
CD4 Antigens
-
Immunosuppressive Agents
-
Interleukin-2 Receptor alpha Subunit
-
Interleukin-7 Receptor alpha Subunit